Rebetol is a widely registered antiviral brand based on ribavirin, with marketing authorisation in 53 countries — a footprint that places it in front of travellers and expatriates across much of Europe, parts of Latin America, North Africa, and Oceania. Its active ingredient is ribavirin, a medication classified within the category of antivirals for systemic use.
Ribavirin is prescribed in the context of viral hepatitis, particularly chronic hepatitis C, and is typically used as one component of a combination antiviral regimen rather than as a standalone therapy. The structured indication list further down this page details the registered uses of Rebetol in the markets where it is authorised, which align with the broader role of ribavirin in the management of chronic viral hepatitis.
Because Rebetol is registered across so many jurisdictions, travellers and expatriates moving between markets may encounter the same medication abroad — sometimes as Rebetol, sometimes as a ribavirin-containing generic, and sometimes as part of a co-packaged regimen. Markets where Rebetol is registered include Australia, France, Egypt, Chile, and the Czech Republic, but regulatory packaging, prescription pathways, and the partner medications used alongside ribavirin vary considerably from one country to another. A pharmacist in any of these markets can confirm whether a locally available ribavirin product corresponds to what was prescribed elsewhere.
Other medications within the broader antivirals-for-systemic-use class are sold internationally under different molecules and brand names, and hepatitis C treatment in particular has evolved significantly in recent years. Anyone managing antiviral therapy across borders should treat substitution as a clinical matter — a healthcare provider familiar with the patient's history and current regimen is the right person to guide it.
3 years
After first opening: the medicinal product should be used within one month.
Not applicable.
Sodium citrate
Citric acid, anhydrous
Sodium benzoate
Glycerol
Sucrose
Sorbitol liquid (crystallising)
Propylene glycol
Purified Water
Natural and artificial bubble gum flavouring
Ribavirin
Ribavirin is embryotoxic or teratogenic, or both, at doses well below the recommended human dose in all animal species in which studies have been conducted. Malformations of the skull, palate, eye, jaw, limbs, skeleton and gastrointestinal tract were noted. The incidence and severity of teratogenic effects increased with escalation of the dose. Survival of foetuses and offspring was reduced.
In a juvenile rat toxicity study, pups dosed from postnatal day 7 to 63 with 10, 25 and 50 mg/kg of ribavirin demonstrated a dose-related decrease in overall growth, which was subsequently manifested as slight decreases in body weight, crown-rump length and bone length. At the end of the recovery period, tibial and femoral changes were minimal although generally statistically significant compared to controls in males at all dose levels and in females dosed with the two highest doses compared to controls. No histopathological effects on bone were observed. No ribavirin effects were observed regarding neurobehavioural or reproductive development. Plasma concentrations achieved in rat pups were below human plasma concentrations at the therapeutic dose.
Erythrocytes are a primary target of toxicity for ribavirin in animal studies. Anaemia occurs shortly after initiation of dosing, but is rapidly reversible upon cessation of treatment.
In 3-and 6-month studies in mice to investigate ribavirin-induced testicular and sperm effects, abnormalities in sperm occurred at doses of 15 mg/kg and above. These doses in animals produce systemic exposures well below those achieved in humans at therapeutic doses. Upon cessation of treatment, essentially total recovery from ribavirin-induced testicular toxicity occurred within one or two spermatogenic cycles.
Genotoxicity studies have demonstrated that ribavirin does exert some genotoxic activity. Ribavirin was active in the Balb/3T3 in vitro transformation assay. Genotoxic activity was observed in the mouse lymphoma assay, and at doses of 20-200 mg/kg in a mouse micronucleus assay. A dominant lethal assay in rats was negative, indicating that if mutations occurred in rats they were not transmitted through male gametes.
Conventional carcinogenicity rodent studies with low exposures compared to human exposure under therapeutic conditions (factor 0.1 in rats and 1 in mice) did not reveal tumorigenicity of ribavirin. In addition, in a 26 week carcinogenicity study using the heterozygous p53(+/-) mouse model, ribavirin did not produce tumours at the maximally tolerated dose of 300 mg/kg (plasma exposure factor approximately 2.5 compared to human exposure). These studies suggest that a carcinogenic potential of ribavirin in humans is unlikely.
Ribavirin plus interferon
When used in combination with peginterferon alfa-2b or interferon alfa-2b, ribavirin did not cause any effects not previously seen with either active substance alone. The major treatment-related change was a reversible mild to moderate anaemia, the severity of which was greater than that produced by either active substance alone.
28 October 2015
Merck Sharp & Dohme Limited
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom
Rebetol oral solution 100 mL is packaged in 118 mL amber glass bottles (coloured EP Type IV glass, Ph Eur.).
The child-resistant cap has inner and outer polypropylene shells.
The 10 mL oral dosing syringe consists of a natural polyethylene barrel, with a white polystyrene plunger rod. Calibrations are marked at 0.5 mL increments from 1.5 mL to 10 mL.
EU/1/99/107/004
Any unused medicinal product or waste material should be disposed of in accordance with local requirements
Date of first authorisation: 25 January 2005
Date of latest renewal: 23 April 2009
Rebetol is prescribed in the management of chronic hepatitis C and other forms of hepatitis as registered in each market. It is typically used as part of a combination antiviral regimen rather than on its own, reflecting standard practice in the treatment of chronic viral hepatitis. The structured indication block further down this page lists each registered use of Rebetol in the countries where it is authorised.
Rebetol contains ribavirin, classified within the broader category of antivirals for systemic use. Ribavirin is the same molecule whether sold under the Rebetol brand or as a generic; internationally, the same active ingredient circulates under multiple commercial names, particularly in markets where several manufacturers produce ribavirin-containing products in parallel for use in hepatitis treatment regimens.
Rebetol is registered in 53 countries, with a footprint that spans Europe, parts of Latin America, North Africa, and Oceania. Representative markets include Australia, France, Egypt, Chile, the Czech Republic, Denmark, and Colombia. If your country is not represented in this list, a local pharmacist can usually confirm whether ribavirin is available in that market under another brand name or as a generic.
Ribavirin is sold under several brand names worldwide, particularly in markets where multiple manufacturers supply the molecule. Other antivirals for systemic use also exist, although they are not interchangeable with ribavirin — hepatitis C therapy in particular has evolved considerably and is highly regimen-specific. To identify a local ribavirin-containing product, search the active ingredient on Pill2Trip or ask a pharmacist in your country.
Yes. Rebetol is a prescription medication, and antiviral therapy for chronic hepatitis C is calibrated to the patient's viral profile, liver status, concurrent medications, and the broader regimen ribavirin is paired with. This is particularly relevant for travellers and people relocating between countries, since available regimens, branded packaging, and prescription pathways differ across regulatory regimes. Any decision to start, stop, or substitute should involve a healthcare provider.
